Oncternal Therapeutics (ONCT) News Today $1.18 +0.04 (+3.51%) (As of 01:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Oncternal Therapeutics Reports Q3 2024 EarningsNovember 21 at 4:48 AM | markets.businessinsider.comOncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.comNovember 19 at 3:09 AM | americanbankingnews.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comOncternal Therapeutics to Cut Most of Its WorkforceNovember 14, 2024 | marketwatch.comStockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)November 13, 2024 | americanbankingnews.comOncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and ImplicationsNovember 9, 2024 | markets.businessinsider.comOncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534October 23, 2024 | markets.businessinsider.comMetastatic Prostate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024October 7, 2024 | theglobeandmail.comNorthland Securities Sticks to Its Buy Rating for Heron Therapeutics (HRTX)September 27, 2024 | markets.businessinsider.comNorthland Capital Markets Downgrades Oncternal Therapeutics (ONCT)September 14, 2024 | msn.comOncternal stock crashes by 60% as it lays off staff and scraps trialsSeptember 14, 2024 | finance.yahoo.comOncternal Therapeutics Cuts Jobs, Discontinues Product Development Amid Business ReviewSeptember 13, 2024 | marketwatch.comOncternal Falls On Discontinuation Of ONCT-534, ONCT-808 Trials; Plans To Explores Strategic OptionsSeptember 12, 2024 | markets.businessinsider.comOncternal plunges on portfolio shakeupSeptember 12, 2024 | msn.comOncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic AlternativesSeptember 12, 2024 | tmcnet.comOncternal Therapeutics Ends Development Activities, Mulls OptionsSeptember 12, 2024 | marketwatch.comContraVir Pharmaceuticals, Inc. (CTRVP)August 22, 2024 | uk.finance.yahoo.comOncternal Therapeutics Second Quarter 2024 Earnings: Beats ExpectationsAugust 11, 2024 | finance.yahoo.comOncternal Therapeutics earnings preview: what to expectAugust 9, 2024 | markets.businessinsider.comONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | investorplace.comOncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comOncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial ResultsAugust 1, 2024 | globenewswire.comOncternal Therapeutics to Present in JonesTrading Healthcare SummitJuly 11, 2024 | globenewswire.comOncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerMay 30, 2024 | globenewswire.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call TranscriptMay 11, 2024 | msn.comQ1 2024 Oncternal Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | msn.comOncternal Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | sfgate.comOncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comOncternal Therapeutics earnings: here's what Wall Street expectsMay 8, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)May 7, 2024 | markets.businessinsider.comOncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)April 23, 2024 | markets.businessinsider.comEwing Sarcoma Drug Pipeline Market Research 2024: Insights About 25+ Companies and 25+ Pipeline DrugsApril 19, 2024 | uk.finance.yahoo.comOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerApril 18, 2024 | globenewswire.comOppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)April 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming CatalystsApril 15, 2024 | markets.businessinsider.com5 Buy-Rated Stocks with Latest Insider PurchasesApril 14, 2024 | insidermonkey.comAIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USAApril 11, 2024 | finance.yahoo.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Acquires $27,650.56 in StockApril 11, 2024 | insidertrades.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills Purchases 6,914 SharesApril 2, 2024 | insidertrades.comOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerMarch 15, 2024 | globenewswire.comNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)March 13, 2024 | markets.businessinsider.comOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 10, 2024 | finance.yahoo.comQ4 2023 Oncternal Therapeutics Inc Earnings CallMarch 8, 2024 | finance.yahoo.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | msn.comOncternal Therapeutics's Earnings: A PreviewMarch 8, 2024 | benzinga.comONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023March 7, 2024 | msn.com Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] ONCT Media Mentions By Week ONCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCT News Sentiment▼-0.110.47▲Average Medical News Sentiment ONCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCT Articles This Week▼51▲ONCT Articles Average Week Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AIM News SLGL News NLSP News SNSE News TLPH News NKGN News AWH News TSBX News CDT News INDP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
